Bedrijven · 27-10-20261 min lezen
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
Lokale automatische vertaling · Oorspronkelijke brontaal
Samenvatting
Teva acquires worldwide rights to BXCL501, expanding its neuroscience pipeline with a potential at-home treatment for agitation currently under FDA review